Together, these results suggest that the BR2-2xPPD peptide is an attractive molecule that can potentially be developed as a targeted therapeutic agent to help treat NSCLC harboring wild-type EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.